These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 20116729)

  • 1. CTX and its role in managing patients exposed to oral bisphosphonates.
    Dodson TB
    J Oral Maxillofac Surg; 2010 Feb; 68(2):487-8; author reply 488-9. PubMed ID: 20116729
    [No Abstract]   [Full Text] [Related]  

  • 2. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment.
    ; Khosla S; Burr D; Cauley J; Dempster DW; Ebeling PR; Felsenberg D; Gagel RF; Gilsanz V; Guise T; Koka S; McCauley LK; McGowan J; McKee MD; Mohla S; Pendrys DG; Raisz LG; Ruggiero SL; Shafer DM; Shum L; Silverman SL; Van Poznak CH; Watts N; Woo SB; Shane E
    J Oral Maxillofac Surg; 2008 Jun; 66(6):1320-1; author reply 1321-2. PubMed ID: 18486811
    [No Abstract]   [Full Text] [Related]  

  • 3. Serum CTX testing.
    Schwartz HC
    J Oral Maxillofac Surg; 2008 Jun; 66(6):1319-20; author reply 1320. PubMed ID: 18486810
    [No Abstract]   [Full Text] [Related]  

  • 4. CTX biochemical marker of bone metabolism. Is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? Part I: biological concepts with a review of the literature.
    Lee CY; Suzuki JB
    Implant Dent; 2009 Dec; 18(6):492-500. PubMed ID: 20009603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteonecrosis of the jaw and biomarkers: what do we tell our patients?
    Koka S
    Int J Oral Maxillofac Implants; 2008; 23(2):179-80. PubMed ID: 18548914
    [No Abstract]   [Full Text] [Related]  

  • 6. Osteonecrosis in the jaws of patients who are using oral biphosphonates to treat osteoporosis.
    Dello Russo NM; Jeffcoat MK; Marx RE; Fugazzotto P
    Int J Oral Maxillofac Implants; 2007; 22(1):146-53. PubMed ID: 17340909
    [No Abstract]   [Full Text] [Related]  

  • 7. Bisphosphonates--what the dentist needs to know: practical considerations.
    Fantasia JE
    J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):53-60. PubMed ID: 19371815
    [No Abstract]   [Full Text] [Related]  

  • 8. Serum CTX to prevent osteonecrosis/orthodontic extraction of third molars: paths toward minimizing surgical risk?
    Assael LA
    J Oral Maxillofac Surg; 2007 Dec; 65(12):2395-6. PubMed ID: 18022460
    [No Abstract]   [Full Text] [Related]  

  • 9. Atraumatic extraction of a non-vital tooth in a patient receiving long-term oral bisphosphonates.
    Xiong M; Pearson A; Sabino M; Svoboda L; Ehlis E
    Northwest Dent; 2010; 89(4):27-33. PubMed ID: 20860270
    [No Abstract]   [Full Text] [Related]  

  • 10. Serologic bone markers for predicting development of osteonecrosis of the jaw in patients receiving bisphosphonates.
    Lazarovici TS; Mesilaty-Gross S; Vered I; Pariente C; Kanety H; Givol N; Yahalom R; Taicher S; Yarom N
    J Oral Maxillofac Surg; 2010 Sep; 68(9):2241-7. PubMed ID: 20728033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonates and bisphosphonate induced osteonecrosis.
    Sawatari Y; Marx RE
    Oral Maxillofac Surg Clin North Am; 2007 Nov; 19(4):487-98, v-vi. PubMed ID: 18088900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment.
    Marx RE; Cillo JE; Ulloa JJ
    J Oral Maxillofac Surg; 2007 Dec; 65(12):2397-410. PubMed ID: 18022461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisphosphonates and bone...what have we learned?
    Guttenberg SA
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Dec; 106(6):769-72. PubMed ID: 18835534
    [No Abstract]   [Full Text] [Related]  

  • 14. Editorial opinion versus real data and knowledge of the literature.
    Marx RE
    Int J Oral Maxillofac Implants; 2008; 23(4):587-8. PubMed ID: 18807554
    [No Abstract]   [Full Text] [Related]  

  • 15. Management of bisphosphonate-induced osteonecrosis of the jaw.
    Schilling J
    Northwest Dent; 2008; 87(3):34-5, 37-8, 40. PubMed ID: 18663869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonates and the dental patient: Part 2.
    Zak M; Spina AM; Spinazze RP; Perkinson WL; Spinazze DJ
    Compend Contin Educ Dent; 2007 Sep; 28(9):510-5; quiz 516, 528. PubMed ID: 17907374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of the clinical implications of bisphosphonates in dentistry.
    Borromeo GL; Tsao CE; Darby IB; Ebeling PR
    Aust Dent J; 2011 Mar; 56(1):2-9. PubMed ID: 21332734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CTX biochemical marker of bone metabolism. Is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? Part II: a prospective clinical study.
    Lee CY; Suzuki JB
    Implant Dent; 2010 Feb; 19(1):29-38. PubMed ID: 20147814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonate-induced osteonecrosis: dental considerations.
    Gross HB
    Compend Contin Educ Dent; 2008 Mar; 29(2):112-3. PubMed ID: 18429426
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws.
    Kunchur R; Need A; Hughes T; Goss A
    J Oral Maxillofac Surg; 2009 Jun; 67(6):1167-73. PubMed ID: 19446200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.